

For brokers and producers only

Date: August 8, 2019

Market: All (except Medicare Supplement)

Medication Prior Authorization Updates

Effective **September 1, 2019**, to ensure safe and effective use of high-cost medications, 11 specialty drugs covered under the medical benefit will require prior authorization. The chart below lists the impacted drugs. Please refer to the [Specialty Drug List](#) to see all medications under the medical benefit that require a prior authorization.

Hemophilia Jivi	Immune Deficiency & Related Disorders Panzyga	Lysosomal Storage Disorder Mepsevii	Mental Health Conditions Spravato, Zulresso
Neuromuscular/Spinal Muscular Atrophy Zolgensma	Oncology Bortezomib, Herceptin Hylecta, Lartruvo	Psoriasis Ilumya	Renal Disease Parsabiv

New to Market, High Impact Drug Prior Authorization Review Process: Zolgensma

[Letters](#) were mailed to 79 impacted members on July 24. Providers were notified via e-blast on July 11.

CVS Caremark is delegated to review prior authorization (PA) requests for drugs covered under the medical benefit to ensure that they meet clinical criteria. However, until drug PA criteria is in effect for new to market, high impact drugs, such as Zolgensma, CareFirst will review these PA requests to ensure appropriate access and use. The PA requests are reviewed on a case-by-case basis by a CareFirst Medical Director who will make a decision based on FDA labeling and clinical trial data.

Prior authorization drug criteria will be available on the CareFirst [provider website](#) by September 1, 2019.

For more information

If you have any questions, please contact your broker sales representative.